CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Phase 1

• Conditions: Lymphomas
• Interventions: Genetic: Anti-CD30 CAR T cells

• Registration Number: NCT02274584
• Lead Sponsor: Peking University

Brief Summary

Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism (FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.

Detailed Description

A large number of lymphoma patients exhaust current treatment options and die from the disease. Innovative therapy is urgently needed. Chimeric antigen receptor (CAR)-modified T cells have demonstrated unprecedented successes in treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell malignancies. Besides CD19 lymphomas, many lymphomas are CD30 positive and therefore, CD30-CAR T cells may prove to be effective in treating such patients. We have developed several generations of CD30 CARs. Preclinical studies have demonstrated effective killing of CD30 target cells. In this study, two versions of CD30 CARs, both of which are 4th generation CARs with a self-withdrawal mechanism (FKBP-iCasp9), will be evaluated in CD30 lymphoma patients. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, tumor targeting and disease status after treatment will also be evaluated.

Study Timeline

• Study Start: 2014-03
• Status Verified: 2014-10
• Study First Submitted: 2014-10-22
• Study First Submitted QC: 2014-10-22
• Last Update Submitted: 2014-10-22
• Study First Posted: 2014-10-24
• Last Update Posted: 2014-10-24
• Primary Completion: 2016-10
• Study Completion: 2017-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Relapsed or refractory CD30(+) lymphoma patients proved by immuno-histochemistry (IHC) or Flow-cytometry.
• Not eligible for autologous stem-cell transplantation (ASCT) or relapsed after ASCT.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Age≥18.
• Pulse oximetry of > 90% on room air.
• Adequate hepatic function, defined as alanine transaminase (ALT) <3 x upper limit of normal (ULN), aspartate aminotransferase (AST) <3 x ULN; serum bilirubin and alkaline phosphatase <2 x ULN.
• Adequate renal function, defined as serum creatinine <2.0mg/dl.
• Adequate heart function with LVEF≥50%
• Hb≥80g/L
• Measurable disease can be identified.
• Life expectancy ≥3 months.
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 1 year after the study is concluded. The male partner should use a condom.
• Patients must sign an informed consent.

Exclusion Criteria

• Uncontrolled active infection.
• Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV).
• HIV positive
• Pregnant or lactating.
• Currently enrolled in another clinical trial.
• Concurrent use of systemic steroids.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CAR T cells	Anti-CD30 CAR T cells	Autologous 4th generation anti-CD30 CAR T cells

Primary Outcome Measures

Name	Time	Method
Number of patients with adverse events.	2 years.	Determine the toxicity profile of the 4th generation CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.

Secondary Outcome Measures

Name	Time	Method
Survival time of the patients.	2 years.	Evaluate the survival time of the patients treated with the 4th generation CAR T cells, including progression free survival (PFS) and overall survival (OS).
Response rates to the 4th generation CAR T cells.	2 years.	Describe the response rates of patients treated with 4th generation CAR T cells, including partial remission (PR), complete remission (CR), stable disease (SD) and progressive disease (PD).
Survival time of Anti-CD30 CAR T cells in vivo.	2 years.	Measure the survival of 4th generation CAR T cells transduced with the anti-CD30 lentiviral vector.

Trial Locations

Locations (2)

Peking University Cancer Hospital; 🇨🇳 Beijing, Beijing, China

University of Florida; 🇺🇸 Gainesville, Florida, United States